Vitamin B6 treatment for tardive dyskinesia: A randomized, double-blind, placebo-controlled, crossover study

Vladimir Lerner, Chanoch Miodownik, Alexander Kaptsan, Yuly Bersudsky, Igor Libov, Ben Ami Sela, Eliezer Witztum

Research output: Contribution to journalArticlepeer-review

81 Scopus citations

Abstract

Background: Tardive dyskinesia (TD) is a significant clinical problem. Vitamin B6 is a potent antioxidant and takes part in almost all of the possible mechanisms that are suggested as being associated with appearance of TD. The aims of this study were (1) to reexamine the efficacy and safety of higher doses of vitamin B6 versus placebo in a greater sample of patients for a longer time and (2) to evaluate the carryover effect of vitamin B6. Method: A 26-week, double-blind, placebo-controlled trial was conducted in a university-based research clinic from August 2002 to January 2005 on 50 inpatients with DSM-IV diagnoses of schizophrenia or schizoaffective disorder and TD. In a double-blind crossover paradigm, all study subjects were randomly assigned to start treatment with either vitamin B6 (daily dose of 1200 mg) or placebo. After 12 weeks of treatment and then a 2-week washout, subjects were crossed over to receive the other treatment for 12 weeks. The primary outcome measure was the change from baseline in Extrapyramidal Symptom Rating Scale (ESRS) scores. Results: The mean decrease in ESRS clinical global impression scores from baseline to endpoint was 2.4 points in patients treated with vitamin B6 and 0.2 points in patients treated with placebo (p < .0001). The mean decrease in the parkinsonism subscale score was 18.5 points and 1.4 points, respectively (p < .00001), and the mean decrease in the dyskinesia subscale score was 5.2 points and -0.8 points, respectively (p < .0001). Conclusion: Vitamin B6 appears to be effective in reducing symptoms of TD. The specific mechanisms by which vitamin B6 attenuates symptoms of TD are not clear.

Original languageEnglish
Pages (from-to)1648-1654
Number of pages7
JournalJournal of Clinical Psychiatry
Volume68
Issue number11
DOIs
StatePublished - 1 Jan 2007

ASJC Scopus subject areas

  • Psychiatry and Mental health

Fingerprint

Dive into the research topics of 'Vitamin B6 treatment for tardive dyskinesia: A randomized, double-blind, placebo-controlled, crossover study'. Together they form a unique fingerprint.

Cite this